4β7整合素抗體（如維多珠單抗、etrolizumab、SHP647），白細(xì)胞介素（IL）-12和IL-23拮抗劑等。對(duì)治療UC單克隆抗體的作用機(jī)制和臨床療效研究進(jìn)展進(jìn)行綜述，以期為該類新藥的研發(fā)及臨床應(yīng)用提供依據(jù)。;The pathogenesis of ulcerative colitis (UC) is complex and related to immune factors and inflammatory mediators. Monoclonal antibodies for specific binding and selectively kill target cells, in vivo distribution is targeting property, less adverse reaction, so become the focus in the treatment of moderately severe UC, including anti-tumor necrosis factor subclass monoclonal antibody (such as infliximab, adamumab, golimumab), Anti-α4β7 integrin antibody (such as vitorizumab, etrolizumab, SHP647), interleukin (IL)-12 and IL-23 antagonists, etc. The mechanism of action and clinical efficacy of monoclonal antibody against UC were reviewed in order to provide evidence for the development and clinical application of this new drug."/> 4β7整合素抗體;IL-23拮抗劑;monoclonal antibodies;ulcerative colitis;tumor necrosis factor α;anti-α4β7 integrin antibody;IL-23 antagonists"/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁(yè) > 過(guò)刊瀏覽>2021年第44卷第1期 >2021,44(1):189-195. DOI:10.7501/j.issn.1674-6376.2021.01.027
上一篇 | 下一篇

單克隆抗體用于治療潰瘍性結(jié)腸炎的研究進(jìn)展

Progress of monoclonal antibody in treatment of ulcerative colitis

發(fā)布日期：2021-01-04
  • 摘要
  • 圖/表
  • 訪問(wèn)統(tǒng)計(jì)
  • PDF預(yù)覽
  • 參考文獻(xiàn)
  • 相似文獻(xiàn)
  • 引證文獻(xiàn)
  • 附件
    [關(guān)鍵詞]
    [摘要]
    潰瘍性結(jié)腸炎（UC）發(fā)病機(jī)制復(fù)雜，與免疫因素及炎性介質(zhì)等因素相關(guān)。單克隆抗體因?yàn)槟芴禺愋越Y(jié)合并選擇性殺傷靶細(xì)胞、體內(nèi)呈靶向性分布、不良反應(yīng)少，所以成為治療中重度UC的研究熱點(diǎn)，其中包括抗腫瘤壞死因子類單抗（如英夫利昔單抗、阿達(dá)木單抗、戈利木單抗），α4β7整合素抗體（如維多珠單抗、etrolizumab、SHP647），白細(xì)胞介素（IL）-12和IL-23拮抗劑等。對(duì)治療UC單克隆抗體的作用機(jī)制和臨床療效研究進(jìn)展進(jìn)行綜述，以期為該類新藥的研發(fā)及臨床應(yīng)用提供依據(jù)。
    [Key word]
    [Abstract]
    The pathogenesis of ulcerative colitis (UC) is complex and related to immune factors and inflammatory mediators. Monoclonal antibodies for specific binding and selectively kill target cells, in vivo distribution is targeting property, less adverse reaction, so become the focus in the treatment of moderately severe UC, including anti-tumor necrosis factor subclass monoclonal antibody (such as infliximab, adamumab, golimumab), Anti-α4β7 integrin antibody (such as vitorizumab, etrolizumab, SHP647), interleukin (IL)-12 and IL-23 antagonists, etc. The mechanism of action and clinical efficacy of monoclonal antibody against UC were reviewed in order to provide evidence for the development and clinical application of this new drug.
    [中圖分類號(hào)]
    R975
    [基金項(xiàng)目]
    國(guó)家自然科學(xué)基金資助項(xiàng)目（81660613）
您是第位訪問(wèn)者
藥物評(píng)價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持：北京勤云科技發(fā)展有限公司
津備案：津ICP備13000267號(hào) 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào)：（津）-非經(jīng)營(yíng)性-2015-0031